Modulation of vincristine and doxorubicin binding and release from silk films

Journal of Controlled Release

Volumn 220, Issue , 2015, Pages 229-238

  Coburn, Jeannine M ^a   Na, Elim ^b   Kaplan, David L ^a  

^a Tufts University   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

Biomaterials; Cancer; Controlled release; Doxorubicin; Silk fibroin; Vincristine

Indexed keywords

AMINO ACIDS; BINS; BIOMATERIALS; CARBOXYLATION; CHEMICAL MODIFICATION; DRUG PRODUCTS; HYDROGELS; IONIC DRUGS; IONIC STRENGTH; MOLECULES; ONCOLOGY; PROTEINS;

CANCER; CONTROLLED RELEASE; DOXORUBICIN; SILK FIBROIN; VINCRISTINE;

DRUG INTERACTIONS;

DIAZONIUM COMPOUND; DOXORUBICIN; SILK; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DELAYED RELEASE FORMULATION; DRUG CARRIER; FIBROIN; PROTEIN BINDING;

ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG RELEASE; HYDROPHOBICITY; IONIC STRENGTH; PH; PRIORITY JOURNAL; PROTON TRANSPORT; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLIZATION; DELAYED RELEASE FORMULATION; DRUG FORMULATION; KINETICS; METABOLISM; PHARMACEUTICS; PROCEDURES; SOLUBILITY; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CRYSTALLIZATION; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; FIBROINS; KINETICS; MOLECULAR STRUCTURE; PROTEIN BINDING; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; VINCRISTINE;

EID: 84945900154     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.10.035     Document Type: Article

References (54)

1. International Agency for Research on Cancer World Cancer Report 2014 February 2014
2. G. Morgan Chemotherapy and the cell cycle Cancer Nurs. Pract. 2 2003 27 30
3. P.J. Hesketh Chemotherapy-induced nausea and vomiting N. Engl. J. Med. 358 2008 2482 2494
4. G. Richardson, and R. Dobish Chemotherapy induced diarrhea J. Oncol. Pharm. Pract. 13 2007 181 198
5. V. Schweitzer Ototoxicity of chemotherapeutic agents Otolaryngol. Clin. N. Am. 26 1993 759 789
6. F. Ries, and J. Klastersky Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity Am. J. Kidney Dis. 8 1986 368 379
7. R. Gale Antineoplastic chemotherapy myelosuppression: mechanisms and new approaches Exp. Hematol. 13 1984 3 7
8. V.B. Pai, and M.C. Nahata Cardiotoxicity of chemotherapeutic agents Drug Saf. 22 2000 263 302
9. S. Quasthoff, and H.P. Hartung Chemotherapy-induced peripheral neuropathy J. Neurol. 249 2002 9 17
10. P. Boffetta, and J.M. Kaldor Secondary malignancies following cancer chemotherapy Acta Oncol. 33 1994 591 598
11. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang, and Y. Barenholz Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res. 54 1994 987 992
12. A.A. Gabizon Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes Cancer Res. 52 1992 891 896
13. H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzym. Regul. 41 2001 189 207
14. M.E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D.G. Kieback, P. Tomczak, S.P. Ackland, F. Orlandi, L. Mellars, L. Alland, and C. Tendler Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 15 2004 440 449
15. I. Fichtner, D. Arndt, B. Elbe, and R. Reszka Cardiotoxicity of free and liposomally encapsulated rubomycin (daunorubicin) in mice Oncology 41 1984 363 369
16. J.A. Silverman, and S.R. Deitcher Marqibo(®) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine Cancer Chemother. Pharmacol. 71 2013 555 564
17. S. Valtonen, U. Timonen, P. Toivanen, H. Kalimo, L. Kivipelto, O. Heiskanen, G. Unsgaard, and T. Kuurne Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study Neurosurgery 41 1997 44 48 discussion 48-49
18. M. Westphal, D.C. Hilt, E. Bortey, P. Delavault, R. Olivares, P.C. Warnke, I.R. Whittle, J. Jääskeläinen, and Z. Ram A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (gliadel wafers) in patients with primary malignant glioma Neuro-Oncology 5 2003 79 88
19. M. Westphal, Z. Ram, V. Riddle, D. Hilt, E. Bortey, and E.C.o.t.G.S. Group Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial Acta Neurochir. 148 2006 269 275
20. T. Yucel, M.L. Lovett, R. Giangregorio, E. Coonahan, and D.L. Kaplan Silk fibroin rods for sustained delivery of breast cancer therapeutics Biomaterials 35 2014 8613 8620
21. D.J. Hines, and D.L. Kaplan Characterization of small molecule controlled release from silk films Macromol. Chem. Phys. 214 2013 280 294
22. E.M. Pritchard, X. Hu, V. Finley, C.K. Kuo, and D.L. Kaplan Effect of silk protein processing on drug delivery from silk films Macromol. Biosci. 13 2013 311 320
23. E.M. Pritchard, C. Szybala, D. Boison, and D.L. Kaplan Silk fibroin encapsulated powder reservoirs for sustained release of adenosine J. Control. Release 144 2010 159 167
24. E.M. Pritchard, T. Valentin, B. Panilaitis, F. Omenetto, and D.L. Kaplan Antibiotic-releasing silk biomaterials for infection prevention and treatment Adv. Funct. Mater. 23 2013 854 861
25. Y. Tian, X. Jiang, X. Chen, Z. Shao, and W. Yang Doxorubicin-loaded magnetic silk fibroin nanoparticles for targeted therapy of multidrug-resistant cancer Adv. Mater. 26 2014 7393 7398
26. F.P. Seib, J. Coburn, I. Konrad, N. Klebanov, G.T. Jones, B. Blackwood, A. Charest, D.L. Kaplan, and B. Chiu Focal therapy of neuroblastoma using silk films to deliver kinase and chemotherapeutic agents in vivo Acta Biomater. 20 2015 32 38
27. B. Chiu, J. Coburn, M. Pilichowska, C. Holcroft, F.P. Seib, A. Charest, and D.L. Kaplan Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model Br. J. Cancer 111 2014 708 715
28. F.P. Seib, and D.L. Kaplan Doxorubicin-loaded silk films: drug-silk interactions and in vivo performance in human orthotopic breast cancer Biomaterials 33 2012 8442 8450
29. F.P. Seib, G.T. Jones, J. Rnjak-Kovacina, Y. Lin, and D.L. Kaplan pH-dependent anticancer drug release from silk nanoparticles Adv. Healthcare Mater. 2 2013 1606 1611
30. F.P. Seib, E.M. Pritchard, and D.L. Kaplan Self-assembling doxorubicin silk hydrogels for the focal treatment of primary breast cancer Adv. Funct. Mater. 23 2013 58 65
31. J. Qu, Y. Liu, Y. Yu, J. Li, J. Luo, and M. Li Silk fibroin nanoparticles prepared by electrospray as controlled release carriers of cisplatin Mater. Sci. Eng. C. Mater. Biol. Appl. 44 2014 166 174
32. A.A. Lozano-Pérez, A.L. Gil, S.A. Pérez, N. Cutillas, H. Meyer, M. Pedreño, D.A.-C. S, C. Janiak, J.L. Cenis, and J. Ruiz Antitumor properties of platinum(iv) prodrug-loaded silk fibroin nanoparticles Dalton Trans. 2015
33. K. Tanaka, K. Mori, and S. Mizuno Immunological identification of the major disulfide-linked light component of silk fibroin J. Biochem. 114 1993 1 4
34. K. Tanaka, S. Inoue, and S. Mizuno Hydrophobic interaction of P25, containing Asn-linked oligosaccharide chains, with the H-L complex of silk fibroin produced by Bombyx mori Insect Biochem. Mol. Biol. 29 1999 269 276
35. C.Z. Zhou, F. Confalonieri, M. Jacquet, R. Perasso, Z.G. Li, and J. Janin Silk fibroin: structural implications of a remarkable amino acid sequence Proteins 44 2001 119 122
36. T. Yucel, M.L. Lovett, and D.L. Kaplan Silk-based biomaterials for sustained drug delivery J. Control. Release 190 2014 381 397
37. A.R. Murphy, and D.L. Kaplan Biomedical applications of chemically-modified silk fibroin J. Mater. Chem. 19 2009 6443 6450
38. A.R. Murphy, P.S. John, and D.L. Kaplan Modification of silk fibroin using diazonium coupling chemistry and the effects on hMSC proliferation and differentiation Biomaterials 29 2008 2829 2838
39. P.N. Atterberry, T.J. Roark, S.Y. Severt, M.L. Schiller, J.M. Antos, and A.R. Murphy Sustained delivery of chemokine CXCL12 from chemically modified silk hydrogels Biomacromolecules 16 2015 1582 1589
40. E. Wenk, A.R. Murphy, D.L. Kaplan, L. Meinel, H.P. Merkle, and L. Uebersax The use of sulfonated silk fibroin derivatives to control binding, delivery and potency of FGF-2 in tissue regeneration Biomaterials 31 2010 1403 1413
41. D.N. Rockwood, R.C. Preda, T. Yucel, X. Wang, M.L. Lovett, and D.L. Kaplan Materials fabrication from Bombyx mori silk fibroin Nat. Protoc. 6 2011 1612 1631
42. B. Lawrence, F. Omenetto, K. Chui, and D. Kaplan Processing methods to control silk fibroin film biomaterial features J. Mater. Sci. 43 2008 6967 6985
43. X. Hu, D. Kaplan, and P. Cebe Determining beta-sheet crystallinity in fibrous proteins by thermal analysis and infrared spectroscopy Macromolecules 39 2006 6161 6170
44. X. Hu, K. Shmelev, L. Sun, E.S. Gil, S.H. Park, P. Cebe, and D.L. Kaplan Regulation of silk material structure by temperature-controlled water vapor annealing Biomacromolecules 12 2011 1686 1696
45. N.A. Guziewicz, A.J. Massetti, B.J. Perez-Ramirez, and D.L. Kaplan Mechanisms of monoclonal antibody stabilization and release from silk biomaterials Biomaterials 34 2013 7766 7775
46. D.M. Byler, and H. Susi Examination of the secondary structure of proteins by deconvolved FTIR spectra Biopolymers 25 1986 469 487
47. E. Goormaghtigh, V. Cabiaux, and J.M. Ruysschaert Secondary structure and dosage of soluble and membrane proteins by attenuated total reflection Fourier-transform infrared spectroscopy on hydrated films Eur. J. Biochem. 193 1990 409 420
48. Q. Lu, X. Hu, X. Wang, J.A. Kluge, S. Lu, P. Cebe, and D.L. Kaplan Water-insoluble silk films with silk I structure Acta Biomater. 6 2010 1380 1387
49. J. Qu, Y. Liu, Y. Yu, J. Li, J. Luo, and M. Li Silk fibroin nanoparticles prepared by electrospray as controlled release carriers of cisplatin Mater. Sci. Eng. C. Mater. Biol. Appl. 44 2014 166 174
50. B.A. Kerwin Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways J. Pharm. Sci. 97 2008 2924 2935
51. C. Sanson, C. Schatz, J.F. Le Meins, A. Soum, J. Thevenot, E. Garanger, and S. Lecommandoux A simple method to achieve high doxorubicin loading in biodegradable polymersomes J. Control. Release 147 2010 428 435
52. L. Gallois, M. Fiallo, A. Laigle, W. Priebe, and A. Garnier-Suillerot The overall partitioning of anthracyclines into phosphatidyl-containing model membranes depends neither on the drug charge nor the presence of anionic phospholipids Eur. J. Biochem. 241 1996 879 887
53. S. Sanli, B. Akmese, N. Sanli, and S. Ozkan A novel RP-LC method for determination of pKa values of some anticancer agents and their assay Chromatographia 76 2013 1467 1475
54. K. Ashutosh Pharmacognosy and pharmacobiotechnology K.K. Gupta, Pharmacognosy And Pharmacobiotechnology 2003 New Age Internation Ltd. New Delhi 432 624